

C3  
C3  
66. (Amended) The [pharmaceutical] composition of claim 65 wherein said plasticizer is diethyl phthalate, triacetin, dibutyl sebacate, dibutyl phthalate or triethyl citrate.

---

C4  
80. (Amended) The [pharmaceutical] composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 1, 55, 2, 48, 56, 49, 57, 58, 50, 16, 19, 51, 52, 53, and 54.

---

C5  
83. (Amended) The [pharmaceutical] composition according to claim 46, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 1, 55, 2, 48, 56, 49, 57, 58, 50, 16, 19, 51, 52, 53, and 54.

---

#### REMARKS

Claims 1-7, 9-20, 46-66, 80 and 83 are pending. Claims 1-7, 9-20, 46-66, 80 and 83 are amended to more clearly describe the claimed inventions. Support for the amendments can be found, for example, in original claim 8 and throughout the specification as originally filed. No new matter has been added.

Claims 1-83 were rejected under 35 U.S.C. § 112, first paragraph, for alleged lack of enablement. Applicants do not concur with the rejection. However, solely for purposes of advancing prosecution, claims 8, 21-45, 67-79 and 81-82 have been canceled and claims 1-7, 9-20, 46-66, 80 and 83 have been amended. Accordingly, Applicants respectfully request reconsideration and withdrawal of the rejection, as it has been rendered moot.

Claims 10, 12, 15, 17-18, 20 and 60-62 were rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite.

Claim 60 and claims 61-62 were rejected under 35 U.S.C. § 112, second paragraph, because it allegedly is not clear whether or not the phrases "bile salts and fatty acids" and "salts" refer to more than one of the recited moieties. Applicants submit that those skilled in the art would appreciate that recitation of "bile salts and fatty acids" and "salts" in Markush format refers to one and more than one bile salt or fatty acid. Accordingly, Applicants respectfully request reconsideration and withdrawal of the rejection.

Claims 10, 12, 15, 17-18 and 20 were rejected under 35 U.S.C. § 112, second paragraph, with respect to the form of the recited Markush group. Applicants have amended the format of the claims, thereby obviating the rejection.

Claims 76-79 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Low et al. Applicants do not concur with the rejection. However, solely in an effort to advance prosecution, Applicants have canceled these claims.

Claims 1-10 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by U.S. Patent No. 5,591,840 to Narayanan et al.(hereinafter "the Narayanan patent"). The Narayanan patent, however, does not disclose penetration enhancers, and, thus, does not anticipate. Applicants respectfully request reconsideration and withdrawal of the rejection.

Claims 80-83 were rejected under 35 U.S.C. § 102(e) as allegedly being anticipated by U.S. Patent No. 6,111,094 to Bennett et al. (hereinafter "the Bennett patent"). Applicants do not concur with the rejection. However, solely for purposes of facilitating


**DOCKET NO.: ISIS-3510**

**PATENT**

prosecution, Applicants have canceled claims 81 and 82. Claims 80 and 83 are not anticipated because they are dependent on claims 1 and 46, respectively, which are not anticipated by the Bennett patent. Accordingly, Applicants respectfully request reconsideration and withdrawal of the rejection.

Applicants respectfully submit that the claims presently before the Examiner patentably define the invention over the prior art and are otherwise in condition for ready allowance.

Respectfully submitted,



**Joseph Lucci**  
Registration No. 33,307

Date: ~~Dec.~~ 8, 2000

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100